First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Conditions:   Platinum Resistant Ovarian Cancer;   Non-Small Cell Lung Cancer, Non-squamous;   Papillary Renal Cell Carcinoma;   Papillary Thyroid Cancer;   Salivary Gland Cancer
Intervention:   Drug: XMT-1536
Sponsors:   Mersana Therapeutics;   Novella Clinical
Not yet recruiting

http://ift.tt/2y3rklV